BioMarin Pharmaceutical, Inc.
(NASDAQ : BMRN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.03%572.252.7%$664.69m
AMGNAmgen, Inc. -0.85%227.021.3%$582.18m
ILMNIllumina, Inc. 2.06%324.413.5%$566.93m
GILDGilead Sciences, Inc. -0.05%60.181.0%$501.10m
MRNAModerna, Inc. 3.57%70.810.0%$488.56m
VRTXVertex Pharmaceuticals, Inc. -0.30%210.741.9%$486.87m
ARRYArray BioPharma Inc. 0.53%39.5514.2%$480.91m
IMMUImmunomedics, Inc. 0.05%87.8611.0%$373.44m
NVAXNovavax, Inc. 2.33%93.2896.5%$309.84m
ALXNAlexion Pharmaceuticals, Inc. 1.66%120.152.0%$285.07m
BIIBBiogen, Inc. -1.88%263.861.6%$259.63m
EXASEXACT Sciences Corp. 7.29%106.8720.7%$235.55m
BNTXBioNTech SE -1.76%86.180.0%$210.90m
SRNESorrento Therapeutics, Inc. 5.09%8.251.4%$190.57m
SGENSeagen Inc. 1.60%200.876.0%$164.96m

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.